The use of PAPRs and SARs is increasing due to potential drug potency exposures during manufacturing and greater awareness of respiratory technology advances.
R&D facility in Minneapolis expands capacity for small molecule development and manufacturing and expansion in Charles City adds QC lab and office space.
A case study on how Recipharm developed a suitable analysis method for Lobsor Pharmaceutical's advanced Parkinson’s disease treatment, Lecigon® intestinal gel.